NeuroNascent, Inc.

Organization DescriptionNeuronascent has discovered and is now developing small molecule therapeutics for neurodegenerative, neurodevelopmental and psychiatric disorders. Neuronascent's founder, Judith Kelleher-Andersson, Ph.D. has been discovering and developing novel therapeutics in the CNS space for over 20 years and has numerous patents related to small molecule neurologic therapeutics. All Neuronascent's technologies were discovered by Kelleher-Andersson after founding Neuronascent. The lead candidate from the pipeline is a non-invasive neuron regenerative therapeutic for Alzheimer's disease and potentially Parkinsons's that the National Institute on Aging supported for all GLP toxicity testing. This patented agent has shown ability to promote new neurons that survive to maturation, which is associated with actual reversal in behavioral impairment in models of disease and aging. Neuronascent aims to initiate first-in-human testing of this safe and efficacious (animal models) therapeutic candidate in 2016, on equity funding and on approval of an IND. Other therapeutic candidates in Neuronascent's pipeline are aimed at post-traumatic stress disorder, Down syndrome, PD and AD.